Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Eiki Kikuchi

Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC

Cancer Research

Oncology

2014

English

A Clinical Analysis of 10 Cases With Oligometastases of Non-Small Cell Carcinoma

Japanese Journal of Lung Cancer

English

Related publications

Rogaratinib: A Potent and Selective Pan-FGFR Inhibitor With Broad Antitumor Activity in FGFR-overexpressing Preclinical Cancer Models

International Journal of Cancer

Cancer Research

Oncology

2019

English

Activation of the Met Kinase Confers Acquired Drug Resistance in FGFR-targeted Lung Cancer Therapy

English

Antitumor Effect of FGFR Inhibitors on a Novel Cholangiocarcinoma Patient Derived Xenograft Mouse Model Endogenously Expressing an FGFR2-CCDC6 Fusion Protein

English

P1.01-72 FIND Trial: A Phase II Study to Evaluate the Efficacy of the FGFR-Inhibitor Erdafitinib in FGFR-Mutated and -Translocated Squamous NSCLC

Journal of Thoracic Oncology

English

Targeting Hepatocarcinogenesis Model in C56BL6 Mice With Pan-Aurora Kinase Inhibitor Danusertib

Journal of Cancer

Oncology

2018

English

Familial Scaphocephaly Syndrome Caused by a Novel Mutation in the FGFR2 Tyrosine Kinase Domain

Journal of Medical Genetics

Genetics

2005

English

Effects of FGFR2 Kinase Activation Loop Dynamics on Catalytic Activity

PLoS Computational Biology

Molecular Neuroscience

English

Development and Validation of a Model to Predict Tyrosine Kinase Inhibitor-Sensitive EGFR Mutations of Non-Small Cell Lung Cancer Based on Multi-Institutional Data

English

MA27.07 Lung Adenocarcinoma Harboring BRAF G469V Mutation Is Uniquely Sensitive to EGFR Tyrosine Kinase Inhibitors

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Eiki Kikuchi

Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC

A Clinical Analysis of 10 Cases With Oligometastases of Non-Small Cell Carcinoma

Related publications

Rogaratinib: A Potent and Selective Pan-FGFR Inhibitor With Broad Antitumor Activity in FGFR-overexpressing Preclinical Cancer Models

Activation of the Met Kinase Confers Acquired Drug Resistance in FGFR-targeted Lung Cancer Therapy

Antitumor Effect of FGFR Inhibitors on a Novel Cholangiocarcinoma Patient Derived Xenograft Mouse Model Endogenously Expressing an FGFR2-CCDC6 Fusion Protein

P1.01-72 FIND Trial: A Phase II Study to Evaluate the Efficacy of the FGFR-Inhibitor Erdafitinib in FGFR-Mutated and -Translocated Squamous NSCLC

Targeting Hepatocarcinogenesis Model in C56BL6 Mice With Pan-Aurora Kinase Inhibitor Danusertib

Familial Scaphocephaly Syndrome Caused by a Novel Mutation in the FGFR2 Tyrosine Kinase Domain

Effects of FGFR2 Kinase Activation Loop Dynamics on Catalytic Activity

Development and Validation of a Model to Predict Tyrosine Kinase Inhibitor-Sensitive EGFR Mutations of Non-Small Cell Lung Cancer Based on Multi-Institutional Data

MA27.07 Lung Adenocarcinoma Harboring BRAF G469V Mutation Is Uniquely Sensitive to EGFR Tyrosine Kinase Inhibitors